

PYC THERAPEUTICS TO HOST Q3 INVESTOR CALL ON 18 AUGUST 2022 9.00AM AWST | 11AM AEST

PYC Therapeutics Limited will host an investor presentation and conference call to provide an update on progress made in the year to date

PERTH, Australia and SAN DIEGO, California – 9 August 2022 – PYC Therapeutics (ASX:PYC) is a biotechnology company combining two complementary platform technologies:

- RNA drug design capabilities; and
- a proprietary drug delivery technology.

Together they are being developed to create a new generation of RNA therapeutics to change the lives of patients with genetic diseases.

PYC Therapeutics CEO Dr. Rohan Hockings will host an investor presentation and conference call on 18 August, 2022 at 9am AWST (11am AEST, 6pm USA PST) to provide an update on progress made in the year to date and outlook for the remainder of 2022.

The investor presentation will be held in the McCusker Auditorium, Harry Perkins Institute, 6 Verdun Street, Nedlands, Western Australia.

The audio and video link to the presentation will be available 15 minutes prior to the commencement of the meeting.

Investors can register for the call via the zoom registration link and submit questions for the Q&A session by emailing info@pyctx.com.

Register in advance for this meeting:

<https://us02web.zoom.us/joining/register/tZ0qceyurjkqG9brfnrqd8xgO1Bp2lY0xeig>

After registering, you will receive a confirmation email containing information about joining the meeting.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a pre-clinical stage biotechnology company pioneering a new generation of RNA therapeutics that utilise the Company's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodegenerative and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are located in Australia and its translational, clinical, regulatory and business development operations are located in the United States. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorized for release by the Board of PYC Therapeutics Limited

CONTACTS:

info@pyctx.com

MEDIA

Michelle Di Lello
michelle.dilello@pyctx.com